Literature DB >> 14871155

Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices.

Rafael de la Torre1, Magí Farré, Mónica Navarro, Roberta Pacifici, Piergiorgio Zuccaro, Simona Pichini.   

Abstract

Consumption of amfetamine-type stimulants, including classical amfetamines and 'designer drugs', has been recognised as one of the most significant trends in drug abuse at the end of the past century and at the beginning of the current one. The first cause is the increasing consumption amongst youth of methylenedioxy- and methoxy-substituted amfetamines, of which the pharmacology in humans is currently under investigation. Secondly, the abuse of more classical amfetamines, such as amfetamine itself and metamfetamine, continues to be highly prevalent in some geographical regions. Amfetamines are powerful psychostimulants, producing increased alertness, wakefulness, insomnia, energy and self-confidence in association with decreased fatigue and appetite as well as enhanced mood, well-being and euphoria. From a clinical pharmacokinetic perspective, amfetamine-type stimulants are rather homogeneous. Their oral bioavailability is good, with a high distribution volume (4 L/kg) and low binding to plasma proteins (less than 20%). The elimination half-life is 6-12 hours. Both hepatic and renal clearance contribute to their elimination from the body. Hepatic metabolism is extensive in most cases, but a significant percentage of the drug always remains unaltered. Amfetamine and related compounds are weak bases, with a pKa around 9.9, and a relatively low molecular weight. These characteristics allow amfetamine-type stimulants to diffuse easily across cell membranes and lipid layers and to those tissues or biological substrates with a more acidic pH than blood, facilitating their detection in alternative matrices at relatively high concentrations. In most cases, the concentrations found are higher than expected from the Henderson-Hasselbach equation. Drug monitoring in non-conventional biological matrices (e.g. saliva, hair, nails, sweat) has recently gained much attention because of its possible applications in clinical and forensic toxicology. An individual's past history of medication, compliance or drug abuse can be obtained from testing of hair and nails, whereas data on current status of drug use can be provided by analysis of sweat and saliva. Because of the physicochemical properties of amfetamine-type stimulants, this group of drugs is one of the most suitable for drug testing in non-conventional matrices.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14871155     DOI: 10.2165/00003088-200443030-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  178 in total

Review 1.  Structure-activity relationships of the classic hallucinogens and their analogs.

Authors:  P Jacob; A T Shulgin
Journal:  NIDA Res Monogr       Date:  1994

2.  Methylenedioxymethamphetamine: a potentially neurotoxic amphetamine analogue.

Authors:  C J Schmidt; L Wu; W Lovenberg
Journal:  Eur J Pharmacol       Date:  1986-05-13       Impact factor: 4.432

3.  Amphetamine metabolism in amphetamine psychosis.

Authors:  E Anggård; L E Jönsson; A L Hogmark; L M Gunne
Journal:  Clin Pharmacol Ther       Date:  1973 Sep-Oct       Impact factor: 6.875

4.  The metabolic fate of 3H-fenetylline in man.

Authors:  T Ellison; L Levy; J W Bolger; R Okun
Journal:  Eur J Pharmacol       Date:  1970       Impact factor: 4.432

Review 5.  Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens.

Authors:  D E Nichols
Journal:  J Psychoactive Drugs       Date:  1986 Oct-Dec

6.  Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans.

Authors:  M Mas; M Farré; R de la Torre; P N Roset; J Ortuño; J Segura; J Camí
Journal:  J Pharmacol Exp Ther       Date:  1999-07       Impact factor: 4.030

7.  Higher cortical and lower subcortical metabolism in detoxified methamphetamine abusers.

Authors:  N D Volkow; L Chang; G J Wang; J S Fowler; D Franceschi; M J Sedler; S J Gatley; R Hitzemann; Y S Ding; C Wong; J Logan
Journal:  Am J Psychiatry       Date:  2001-03       Impact factor: 18.112

Review 8.  Methamphetamine and methylenedioxymethamphetamine neurotoxicity: possible mechanisms of cell destruction.

Authors:  L S Seiden; K E Sabol
Journal:  NIDA Res Monogr       Date:  1996

9.  Steady-state pharmacokinetics of phentermine extended-release capsules.

Authors:  G Groenewoud; R Schall; H K Hundt; F O Müller; M van Dyk
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1993-08

10.  Further evidence that amphetamines produce long-lasting dopamine neurochemical deficits by destroying dopamine nerve fibers.

Authors:  G A Ricaurte; L S Seiden; C R Schuster
Journal:  Brain Res       Date:  1984-06-15       Impact factor: 3.252

View more
  26 in total

1.  Consumption of palatable food decreases the anorectic effects of serotonergic, but not dopaminergic drugs in baboons.

Authors:  Richard W Foltin
Journal:  Physiol Behav       Date:  2011-04-13

Review 2.  Interpretation of oral fluid tests for drugs of abuse.

Authors:  Edward J Cone; Marilyn A Huestis
Journal:  Ann N Y Acad Sci       Date:  2007-03-01       Impact factor: 5.691

3.  Medico-legal assessment of methamphetamine and amphetamine serum concentrations-what can we learn from survived intoxications?

Authors:  Marco Weber; Rüdiger Lessig; Carolin Richter; Axel P Ritter; Ilona Weiß
Journal:  Int J Legal Med       Date:  2017-05-16       Impact factor: 2.686

4.  Interaction and Transport of Methamphetamine and its Primary Metabolites by Organic Cation and Multidrug and Toxin Extrusion Transporters.

Authors:  David J Wagner; Jennifer E Sager; Haichuan Duan; Nina Isoherranen; Joanne Wang
Journal:  Drug Metab Dispos       Date:  2017-04-20       Impact factor: 3.922

Review 5.  Lisdexamfetamine.

Authors:  Stephanie K A Blick; Gillian M Keating
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

6.  Excretion of methamphetamine and amphetamine in human sweat following controlled oral methamphetamine administration.

Authors:  Allan J Barnes; Michael L Smith; Sherri L Kacinko; Eugene W Schwilke; Edward J Cone; Eric T Moolchan; Marilyn A Huestis
Journal:  Clin Chem       Date:  2007-11-02       Impact factor: 8.327

7.  The amphetamine response moderates the relationship between negative emotionality and alcohol use.

Authors:  Kenneth J D Allen; Frances H Gabbay
Journal:  Alcohol Clin Exp Res       Date:  2012-12-14       Impact factor: 3.455

8.  Bottoms up: methamphetamine toxicity from an unusual route.

Authors:  Malkeet Gupta; Scott Bailey; Luis M Lovato
Journal:  West J Emerg Med       Date:  2009-02

9.  Excretion of Delta9-tetrahydrocannabinol in sweat.

Authors:  Marilyn A Huestis; Karl B Scheidweiler; Takeshi Saito; Neil Fortner; Tsadik Abraham; Richard A Gustafson; Michael L Smith
Journal:  Forensic Sci Int       Date:  2007-05-03       Impact factor: 2.395

Review 10.  Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview.

Authors:  João Paulo Capela; Helena Carmo; Fernando Remião; Maria Lourdes Bastos; Andreas Meisel; Félix Carvalho
Journal:  Mol Neurobiol       Date:  2009-04-17       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.